Diabetes, Vol 46, Issue 10 1612-1618, Copyright © 1997 by American Diabetes Association

ARTICLES

Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies

TJ Allen, Z Cao, S Youssef, UL Hulthen and ME Cooper
Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Australia.

We explored the relative roles of the suppression of angiotensin II and the prevention of bradykinin degradation in mediating the renoprotective effects of ACE inhibitors in experimental diabetic nephropathy. Over a 24-week period, we studied male Sprague-Dawley diabetic and control rats and Sprague-Dawley diabetic rats treated with the ACE inhibitor ramipril, the angiotensin II-AT1 receptor antagonist valsartan, the bradykinin-B2 receptor antagonist HOE 140 (icatibant), and a combination of ramipril and icatibant. Serial measurements of urinary albumin excretion, blood pressure, and glycated hemoglobin were performed monthly. After 6 months, the animals were killed for the measurement of kidney weight and the assessment of glomerular ultrastructure. Over 24 weeks, urinary albumin excretion showed a continuous rise in the untreated diabetic rats. Both ramipril and valsartan, which were equihypotensive, prevented the increase in urinary albumin excretion over the whole study period. Icatibant therapy did not attenuate the antialbuminuric effect of the ACE inhibitor, nor did it have any effect as the sole therapy. Diabetes was associated with increased glomerular basement membrane thickness, glomerular volume, and total mesangial volume. Both ACE inhibition and angiotensin II receptor antagonism attenuated the glomerular ultrastructural changes to a similar degree. Icatibant did not attenuate the effects of ramipril on glomerular morphology. ACE inhibitors and angiotensin II-AT1 receptor blockers appear to confer similar benefits in experimental diabetic nephropathy, and bradykinin-B2 receptor blockers do not influence this effect. These findings suggest that the blockade of angiotensin II is the major pathway responsible for renoprotection afforded by ACE inhibition in experimental diabetic nephropathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256. [Abstract] [Full Text] [PDF]

				H. Okada, T. Inoue, T. Kikuta, Y. Watanabe, Y. Kanno, S. Ban, T. Sugaya, M. Horiuchi, and H. Suzuki A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade Am. J. Pathol., November 1, 2006; 169(5): 1577 - 1589. [Abstract] [Full Text] [PDF]

				M. C. Thomas, C. Tikellis, W. M. Burns, K. Bialkowski, Z. Cao, M. T. Coughlan, K. Jandeleit-Dahm, M. E. Cooper, and J. M. Forbes Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2976 - 2984. [Abstract] [Full Text] [PDF]

				P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]

				C. Tikellis, P. J. Wookey, R. Candido, S. Andrikopoulos, M. C. Thomas, and M. E. Cooper Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat Diabetes, April 1, 2004; 53(4): 989 - 997. [Abstract] [Full Text] [PDF]

				C. Tikellis, C. I. Johnston, J. M. Forbes, W. C. Burns, L. M. Burrell, J. Risvanis, and M. E. Cooper Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy Hypertension, March 1, 2003; 41(3): 392 - 397. [Abstract] [Full Text] [PDF]

				F. C. Sasso, O. Carbonara, M. Persico, D. Iafusco, T. Salvatore, R. D'Ambrosio, R. Torella, and D. Cozzolino Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension: A randomized double-blind placebo-controlled crossover study Diabetes Care, November 1, 2002; 25(11): 1909 - 1913. [Abstract] [Full Text] [PDF]

				S. A. Mifsud, S. L. Skinner, M. E. Cooper, D. J. Kelly, and J. L. Wilkinson-Berka Effects of Low-Dose and Early versus Late Perindopril Treatment on the Progression of Severe Diabetic Nephropathy in (mREN-2)27 Rats J. Am. Soc. Nephrol., March 1, 2002; 13(3): 684 - 692. [Abstract] [Full Text] [PDF]

				M. W. TAAL, V. D. NENOV, W. WONG, S. R. SATYAL, O. SAKHAROVA, J. H. CHOI, J. L. TROY, and B. M. BRENNER Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2051 - 2059. [Abstract] [Full Text] [PDF]

				J. L. Wilkinson-Berka, N. J. Gibbs, M. E. Cooper, S. L. Skinner, and D. J. Kelly Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1343 - 1349. [Abstract] [Full Text] [PDF]

				R. Toto Angiotensin II Subtype 1 Receptor Blockers and Renal Function Arch Intern Med, June 25, 2001; 161(12): 1492 - 1499. [Abstract] [Full Text] [PDF]

				M. W. Taal, G. M. Chertow, H. G. Rennke, A. Gurnani, T. Jiang, A. Shahsafaei, J. L. Troy, B. M. Brenner, and H. S. Mackenzie Mechanisms underlying renoprotection during renin-angiotensin system blockade Am J Physiol Renal Physiol, February 1, 2001; 280(2): F343 - F355. [Abstract] [Full Text] [PDF]

				C. E. Mogensen, S. Neldam, I. Tikkanen, S. Oren, R. Viskoper, R. W Watts, and M. E Cooper Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ, December 9, 2000; 321(7274): 1440 - 1444. [Abstract] [Full Text]

				Z. Cao, M. E. Cooper, L. L. Wu, A. J. Cox, K. Jandeleit-Dahm, D. J. Kelly, and R. E. Gilbert Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury Hypertension, October 1, 2000; 36(4): 561 - 568. [Abstract] [Full Text] [PDF]

				E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]

				F. Amiri and R. Garcia Renal angiotensin II receptors and protein kinase C in diabetic rats: effects of insulin and ACE inhibition Am J Physiol Renal Physiol, April 1, 2000; 278(4): F603 - F612. [Abstract] [Full Text] [PDF]

				D. Wang, H. Yoshida, Q. Song, L. Chao, and J. Chao Enhanced renal function in bradykinin B2 receptor transgenic mice Am J Physiol Renal Physiol, March 1, 2000; 278(3): F484 - F491. [Abstract] [Full Text] [PDF]

				C. Tschope, A. Reinecke, U. Seidl, M. Yu, V. Gavriluk, U. Riester, P. Gohlke, K. Graf, M. Bader, U. Hilgenfeldt, et al. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2333 - H2340. [Abstract] [Full Text] [PDF]

				M. J. ZYCHMA, J. GUMPRECHT, E. ZUKOWSKA-SZCZECHOWSKA, and W. GRZESZCZAK Polymorphisms in the Genes Encoding for Human Kinin Receptors and the Risk of End-Stage Renal Failure: Results of Transmission/DisequilibriumTest J. Am. Soc. Nephrol., October 1, 1999; 10(10): 2120 - 2124. [Abstract] [Full Text]